$92.09
+1.49 (+1.64%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MDT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 37 observational · 4 with posted results
Held by 22 tracked-famous managers (First Eagle Investment Management, LLC, Dodge & Cox, CITADEL ADVISORS LLC, D. E. Shaw & Co., Inc., JANE STREET GROUP, LLC, +17 more) · FINRA short interest 2.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: 2 congress / 8 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy ProductsNCT00271180observationalLead related complications for each lead model. | — | Recruiting | Device | Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia | 20,000 | Dec 2040 | ≤ 5,248 d | 2026-05-07 |
| Product Surveillance RegistryNCT01524276observationalSafety and Effectiveness of Market Released products | — | Recruiting | — | Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder | 100,000 | Jan 2040 | ≤ 4,913 d | 2026-08-18 |
| Lead Evaluation for Defibrillation and Reliability Post Approval StudyNCT07005232observationalComplication Survival Rate | — | Enrolling by invitation | Device: defibrillation lead | Tachyarrhythmia | 2,000 | Sep 2032 | ≤ 2,234 d | 2026-08-03 |
| Enlighten Study: The EV-ICD Post Approval RegistryNCT06048731observationalComplication-free survival rate | — | Active, not recruiting | Device: Defibrillation using EV-ICD | Ventricular Arrhythmia, Tachycardia | 1,000 | 2030-05-31 | in 1,381 d | 2025-07-30 |
| Longitudinal Coverage With Evidence Development Study on Micra Leadless PacemakersNCT03039712observationalAcute complication rate | — | Active, not recruiting | — | Bradycardia | 37,000 | Jun 2029 | ≤ 1,046 d | 2025-09-29 |
| Longitudinal Coverage With Evidence Development Study on Micra AV Leadless Pacemakers (Micra AV CED)NCT04235491observationalAcute complication rate | — | Active, not recruiting | — | Bradycardia | 37,000 | Jun 2029 | ≤ 1,046 d | 2025-09-29 |
| Post Market Evaluation of Real World Outcomes and Durability to Support Implantable Inceptiv™ Spinal Cord Stimulation TherapyNCT07507422observationalPercentage of implanted patients who have a ≥ 50% improvement in pain score as assessed by numeric pain rating scale (NPRS) from baseline for the predominant pain being treated at 6 months following device activation | — | Recruiting | Device: Commercially available Inceptiv™ neurostimulation systems | Chronic Pain, Intractable Pain | 970 | 2029-06-27 | in 1,043 d | 2026-05-04 |
| Personalized Therapy Study - Attain Stability Quad Post-Approval StudyNCT04024943observationalPercentage of patients without a lead- related event at 5 years post-implant | — | Active, not recruiting | Device: Quadripolar LV Lead | Heart Failure | 1,092 | Jul 2027 | ≤ 346 d | 2026-02-04 |
| Propel Drug-Eluting Sinus Implant Family IBUKI CohortNCT07546682observationalSNOT-22 total score change | — | Recruiting | Other: None, observational standard of care study | Chronic Rhinosinusitis (CRS) | 100 | May 2027 | ≤ 285 d | 2026-04-23 |
| Micra Transcatheter Pacing System Post-Approval RegistryNCT02536118observationalAcute complication rate | — | Active, not recruiting | Device: Micra Transcatheter Pacing System | Bradycardia | 3,100 | Apr 2027 | ≤ 254 d | 2026-02-04 |
| IN.PACT™ AV Access Post-Approval Study (PAS002)NCT04543539observationalInfection and Infestations Serious Adverse Events | — | Active, not recruiting | Combination product: IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort, IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort | Arteriovenous Fistula, Arteriovenous Fistula Stenosis, Arteriovenous Fistula Occlusion, Fistula | 240 | 2025-06-03actual | — | 2025-10-20 |
| Personalized Therapy Study - HFRS (TriageHF) Post Approval StudyNCT04489225observationalpositive predictive value (PPV) of HFRS High Risk Status associated with worsening heart failure | — | Active, not recruiting | Other: Observational | Heart Failure | 2,200 | 2024-12-06actual | — | 2025-10-20 |
| Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)NCT04496518observationalTo demonstrate the success rate of iATP in the fast VT (FVT) zone is greater than 60% | — | Active, not recruiting | Device: Intrinsic Antitachycardia Pacing (iATP) Therapy | Ventricular Tachycardia | 2,200 | 2024-11-06actual | — | 2025-10-20 |
| Product Surveillance Registry; Ear, Nose and Throat - EXTEND CohortNCT06671561observationalTo characterize the SNOT-22 total score change from baseline to Month 6 in patients with CRS undergoing FESS | — | Withdrawnsponsor's stated reason: New study design and data collection needed | Device: Observational data collection from patients with chronic rhinosinusitis (CRS) receiving PROPEL sinus implant(s) following functional endoscopic sinus surgery (FESS) | Chronic Rhinosinusitis (CRS) | 0 | Aug 2026 | ≤ 12 d | 2025-05-15 |
| Micra AV Transcatheter Pacing System Post-Approval RegistryNCT04253184observationalRate of pacemaker syndrome | — | Completed | Device: Micra AV Transcatheter Pacing System | Bradycardia | 802 | 2025-09-05actual | — | 2026-02-04 |
| Product Surveillance Registry; Ear, Nose &Amp; Throat - NIM Vital CohortNCT06637995observationalAdverse Event Rate | — | Completed | Device: Intraoperative Nerve Monitoring | Intracranial Surgery, Extracranial Surgery, Intratemporal Surgery, Extratemporal Surgery, Neck Surgery, Spine Surgery, Thoracic Surgery, Upper Extremity Surgery, Lower Extremity Surgery | 205 | 2025-07-03actual | — | 2025-09-24 |
| Propel Drug-Eluting Sinus Stent Family Open CohortNCT05925985observationalLong-term safety and efficacy of corticosteroid-eluting implants in patients with CRS undergoing Functional Endoscopic Sinus Surgery (FESS) | — | Completed | Other: NA-Observational Registry | Chronic Rhinosinusitis (Diagnosis) | 215 | 2025-02-19actual | — | 2026-01-20 |
| Medtronic Signia SDR Product Surveillance RegistryNCT05095935results2026-01-07observationalIncidence of Intraoperative Hemostatic InterventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Other: N/A observational registry | Minimally Invasive Surgical Procedures, Surgical Procedures, Operative | 430 | 2024-10-01actual | — | 2026-01-07 |
| Medtronic PSR TDD PMCFNCT04714385observationalPump accuracy | — | Completed | — | Chronic Pain, Spasticity, Muscle | 209 | 2024-01-18actual | — | 2024-06-04 |
| IN.PACT™ Quality of Life Post-Reimbursement StudyNCT04597307observationalQuality of Life EQ-5D-5L French Index Score Change | — | Unknown status | Combination product: IN.PACT™ Admiral™ Drug Coated Balloon (DCB) | Obstructive Disease, Atherosclerosis of Femoral Artery, Atherosclerosis of Popliteal Artery | 80 | 2023-11-08actual | — | 2024-03-15 |
| ExtraVascular Implantable Cardiac Defibrillator Continued Access StudyNCT05049720ComplicationsOpen-label · Other | Not applicable | Withdrawnsponsor's stated reason: The NCT posting for the study has been transferred to NCT04060680 | Device: Defibrillation using the Extravascular ICD | Tachycardia, Ventricular Arrythmia | 0 | 2023-07-28 | — | 2022-09-10 |
| The Product Surveillance Registry REVERSE Post Approval StudyNCT01660035observationalSurvival from Heart Failure Hospitalization and All-Cause Mortality | — | Completed | — | Heart Failure | 155 | Apr 2022actual | — | 2022-04-18 |
| Personalized CRT - PSRNCT03723265observationalCRT Response | — | Completed | Device: Cardiac Resynchronization Therapy | Heart Failure | 1,517 | 2022-04-28actual | — | 2022-05-20 |
| 3T MRI CIED Post-Approval StudyNCT02969395observationalThe proportion of patients implanted with an MR Conditional CIED System with a pre-MRI to post-MRI scan PCT measure change of >0.5 Volts following 3T MRI scan exposure. | — | Completed | — | Cardiac Rhythm Disorder | 41 | 2021-10-15actual | — | 2022-08-22 |
| Attain Performa™ Left Ventricular (LV) Quadripolar Leads Chronic Performance StudyNCT02294331observationalLead complication | — | Completed | — | Heart Failure | 1,900 | 2021-07-31actual | — | 2022-02-01 |
| Personalized CRT - MPP Post Approval StudyNCT03232944observationalMPP therapy responder | — | Completed | Device: Cardiac Resynchronization Therapy - MPP | Heart Failure | 1,338 | 2020-06-04actual | — | 2021-02-17 |
| Model 4396 Left Ventricular (LV) Lead Chronic Performance StudyNCT01361685observationalModel 4396 LV Lead-related complication rate | — | Completed | — | Heart Failure | 366 | 2020-03-02actual | — | 2021-02-17 |
| Model 4296 Left Ventricular (LV) Lead Chronic Performance StudyNCT01361672observationalModel 4296 LV Lead-related complication rate | — | Completed | — | Heart Failure | 1,140 | Jul 2019actual | — | 2019-07-22 |
| DF4 Connector System Post-Approval StudyNCT01638897observationalDF4 Lead Related Complication Rate | — | Completed | — | Ventricular Tachycardia, Ventricular Fibrillation, Sudden Cardiac Death, Heart Failure | 1,778 | Mar 2019actual | — | 2019-03-20 |
| Magnetic Resonance (MR) Conditional Tachyarrhythmia Therapy Products Post-approval StudyNCT02849769observationalThe proportion of episodes with ≥ 5 seconds VF detection delay in the MR conditional tachyarrhythmia therapy system following MRI exposure. | — | Completed | Device: Implant of an MR-conditional Tachy device system | Tachyarrhythmia | 10,979 | Dec 2018actual | — | 2019-06-05 |
| Model 4195 Left Ventricular (LV) Lead Chronic Performance StudyNCT00869921observationalLead-related complication rate. | — | Completed | — | Heart Failure | 1,322 | 2018-04-03actual | — | 2018-09-13 |
| SureScan Post-Approval StudyNCT01299675observationalMRI Related Complication Rate | — | Completed | — | Bradycardia | 2,483 | 2017-10-02actual | — | 2018-04-27 |
| Model 4196 Left Ventricular (LV) Lead Chronic Performance StudyNCT00930904observationalLead-related complication rate | — | Completed | — | Heart Failure | 1,847 | Apr 2017actual | — | 2017-12-27 |
| Micra Transcatheter Pacing System Continued Access Study ProtocolNCT02488681results2018-01-03ComplicationsOpen-label · Treatment | Not applicable | Completed | Device: Micra Pacemaker Implant | Bradycardia | 285 | Jul 2016actual | — | 2018-04-12 |
| MEDTRONIC ADAPTA, VERSA AND SENSIA nEw3 POST APPROVAL STUDYNCT01076374observationalRate of device malfunctions | — | Completed | — | Arrhythmia, Bradycardia | 2,927 | Oct 2015actual | — | 2018-04-26 |
| Integrated Diagnostic for Heart FailureNCT01798797observationalHeart Failure Risk Status Performance Characterization | — | Completed | — | Heart Failure | 100 | Jul 2015actual | — | 2018-09-25 |
| Model 4965 Post-Approval StudyNCT01076348results2012-08-23observationalModel 4965 Complication Free Rate | — | Completed | — | Heart Failure, Pacing, Bradycardia, Arrhythmia | 73 | Apr 2011actual | — | 2019-02-27 |
| Enhanced Surveillance of RV Lead Integrity Alert (RVLIA)NCT00824915observationalSensitivity of the LIA algorithm | — | Completed | — | Shock | 1,779 | Feb 2011actual | — | 2018-03-02 |
| Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval StudyNCT01076361results2014-10-27observationalSurvival Probability of the Model 4968 Lead Based on Lead-related Complications | — | Completed | — | Arrhythmia, Heart Failure | 370 | Sep 2010actual | — | 2014-10-27 |
| Platelets for Acute Wound HealingNCT00125086Time to 100% wound closure, measured at Days 7, 14, 21, 28, 35Randomized · Double-masked · Treatment | Not applicable | Completed | Device: autologous platelet gel | Wounds | 4 | — | — | 2005-09-14 |
| Comparison of SCS and PMR in Patients With Refractory Angina PectorisNCT00157742Improvement in total exercice time following SCS compared to PMR at 12 monthsRandomized · Open-label · Treatment | Phase 4 | Terminated | Procedure: Spinal Cord Stimulation (SCS), Percutaneous Myocardial Laser Revascularisation (PMR) | Angina Pectoris | 66 | — | — | 2005-12-16 |
| Platelets in Acute Wounds: A Pilot Study (PAWS)NCT00199992Time to complete closureNon-randomized · Open-label · Treatment | Not applicable | Completed | Procedure: application of autologous platelet gel | Wounds | 8 | — | — | 2005-09-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19